Answers are grounded in this paper and cite their sources.
Background: Non-epithelial ovarian tumors represent a rare and heterogeneous group of malignancies, accounting for a minority of ovarian cancers but occurring more frequently in young women. Because of their rarity and diverse clinical and histopathological profiles, these tumors remain less well characterized than epithelial ovarian cancers. Objectives: This study aimed to describe the epidemiological, clinical, paraclinical, and pathological characteristics of non-epithelial ovarian tumors, as well as assess therapeutic strategies and clinical outcomes, through a retrospective analysis of 18 cases. A complementary literature review was undertaken to contextualize our findings. Methods: A retrospective descriptive study was conducted at the Medical Oncology Department of CHU Ibn Rochd, Casablanca, including all histologically confirmed malignant non-epithelial ovarian tumors diagnosed between January 2021 and December 2022. Clinical presentation, imaging findings, tumor markers, histological subtypes, treatments, and outcomes were analyzed. Results: Of 140 ovarian cancer cases, 18 (12.8%) were non-epithelial tumors. Sex cord–stromal tumors were the most common (60%), followed by germ cell tumors. The mean age at diagnosis was 46.5 years for stromal tumors and 32.5 years for germ cell tumors. Abdominal distension (42%) and pelvic pain (30%) were the most frequent presenting symptoms. Imaging identified adnexal masses in most cases, consistent with reported high diagnostic performance of pelvic ultrasound and CT in ovarian tumor assessment [1,2]. Tumor marker evaluation showed variable elevations depending on tumor subtype, supporting existing recommendations for hCG, AFP, LDH, CA-125 and inhibin B testing [3,4]. All patients underwent surgery, with radical procedures performed in 60% of cases. First-line chemotherapy—primarily BEP or paclitaxel–carboplatin—was administered to 38% of patients, in accordance with current standards for germ cell tumors [4–6]. Complete remission at 6 months was achieved in 33% of cases, while relapse occurred in 22% and metastases in 16%. Overall survival in our series was 66%, lower than SEER- reported survival figures for similar tumor categories [7]. Conclusion: Non- epithelial ovarian tumors, although uncommon, require early diagnosis and individualized management due to their heterogeneous biological behavior and their predominance in young women. Fertility-sparing surgery and platinum-based chemotherapy remain key therapeutic strategies. Despite favorable initial responses, recurrence rates emphasize the importance of long-term surveillance and personalized treatment approaches.
No takes yet. Share an insight, caveat, or question.
Safi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: